Dana Wilkins currently holds the role of Chief Operating Officer (COO) at ProSciento. Before taking on this position, she served as the Vice President of Quality and Regulatory Compliance. With a distinguished career spanning more than 25 years, Ms. Wilkins has established herself as a renowned expert in clinical research operations, regulatory compliance, and quality management systems.
Prior to joining ProSciento, Ms. Wilkins served as the Executive Director of Quality Assurance at Rho, Inc. In this role, she played a pivotal part in crafting an advanced quality management system. Her contributions were highlighted by the establishment of a Quality Board and the implementation of robust processes, fostering a culture of quality across every phase of project development.
Ms. Wilkins’ career history also includes significant roles at BioMerieux, Inc., a leader in in-vitro diagnostics. Here, she held various quality leadership positions, including Global Director of Clinical Operations and the vital role as a Global Quality Board member. In this capacity, she was tasked with upholding and elevating quality standards throughout the realms of Medical Affairs, Clinical Affairs, and Regulatory Affairs. Ms. Wilkins’ leadership played a pivotal role in steering the FDA’s groundbreaking achievement—the clearance of the first 510k IVD product based on meta-analysis. Before her tenure at BioMerieux, she served as the Director of Clinical Research Operations at Lehigh Valley Health Network. Ms. Wilkins is a registered nurse and completed an M.S. in Health Services Administration from the University of St. Francis.
